Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer

• Status: Unknown status
• Trial end date: 2019-03-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the present study is to evaluate the efficacy and safety of Maekmoondong-tang on post-operative cough in patients with lung cancer. A randomized, double-blind, placebo-controlled trial will be conducted.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seong-Gyu Ko

Criteria

Inclusion Criteria:

• Adults over 20 years old.

• Patients undergone segmentectomy or lobectomy for lung cancer within 1 month

• Patients who do not or poorly respond to one week administration of common antitussive agents.

• Eastern Cooperative Oncology Group(ECOG) 0 to 2

• Participant is willing and able to give informed consent for participation in the study

Exclusion Criteria:

• Patients undergoing adjuvant chemotherapy.

• Patients who have been diagnosed with acute respiratory disease within 1 month.

• Patients who have been diagnosed with bronchial asthma or bronchiectasis within 1 year

• Patients taking Angiotensin Converting Enzyme Inhibitor

• Patients with pseudoaldosteronism.

• Participants who have known prior hypersensitivity to any investigational product component

• Patient with acute or chronic infections requiring treatment (active HAV, HBV, HCV, HIV, TB)

• Pregnant or lactating females

• Women of childbearing potential

• Patient who do not agrees to use effective means of contraception and not to donate sperm during the trial and up to 1 month after final administration

• Patient who participated other clinical trials of medicine or medical devices within 1 month

• Individuals who are judged inappropriate for the study by investigator